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A B S T R A C T
The GABAA receptor (GABAAR) is a major target of antiseizure drugs (ASDs). A variety of agents that act at
GABAARs s are used to terminate or prevent seizures. Many act at distinct receptor sites determined by
the subunit composition of the holoreceptor. For the benzodiazepines, barbiturates, and loreclezole,
actions at the GABAAR are the primary or only known mechanism of antiseizure action. For topiramate,
felbamate, retigabine, losigamone and stiripentol, GABAAR modulation is one of several possible
antiseizure mechanisms. Allopregnanolone, a progesterone metabolite that enhances GABAAR function,
led to the development of ganaxolone. Other agents modulate GABAergic ‘‘tone’’ by regulating the
synthesis, transport or breakdown of GABA. GABAAR efﬁcacy is also affected by the transmembrane
chloride gradient, which changes during development and in chronic epilepsy. This may provide an
additional target for ‘‘GABAergic’’ ASDs. GABAAR subunit changes occur both acutely during status
epilepticus and in chronic epilepsy, which alter both intrinsic GABAAR function and the response to
GABAAR-acting ASDs. Manipulation of subunit expression patterns or novel ASDs targeting the altered
receptors may provide a novel approach for seizure prevention.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eizSeizures frequently result from an imbalance of excitation and
inhibition due to a failure of inhibitory neurotransmission. Most
agents that enhance GABAA receptor (GABAAR) function have
antiseizure properties due to their ability to increase inhibitory
neurotransmitter tone. The evidence linking epilepsy with
dysfunction of GABAergic inhibition is substantial, and has been
extensively reviewed1–4.
1. GABAARs and epilepsy
GABAARs are pharmacologically complex, with binding sites for
benzodiazepines (BZs), barbiturates, neurosteroids, general anes-
thetics, loreclezole, and the convulsant toxins, picrotoxin and
bicuculline. Protein subunits from seven different subunit fami-
lies5 assemble to form pentameric6 transmembrane chloride
channels (Fig. 1). In mammals, 16 subunit subtypes have been
cloned, including 6 a, 3 b and 3 g subtypes, as well as d, p7, e8 and
u9 and alternatively spliced variants of the b2 and g2 subtypes.
Subunit expression is regulated by region, cell type10 and
developmental stage11, reducing the number of isoforms
expressed in speciﬁc brain regions and individual neurons. The
most common composition includes two a1, two b2 and a single
g2 subunit; the d subunit is found instead of g in receptors
expressed extrasynaptically. The subunits are arranged around a* Tel.: +1 501 686 7236; fax: +1 501 686 7850.
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http://dx.doi.org/10.1016/j.seizure.2013.04.015central water-ﬁlled pore, which gates to conduct Cl ions when
GABA is bound (Fig. 1). Individual subunit subtypes confer
different sensitivities to GABAAR modulators including BZs
12,
loreclezole13 and zinc ions14 (Table 1).
GABAARs are the target not only of the BZs, but other ASDs
including barbiturates and agents like tiagabine and vigabatrin1
that increase GABA concentration at the synapse. Bicuculline and
picrotoxin, which are GABAAR antagonists, induce seizures in
animals and epileptiform activity in brain slice preparations.
Several animal models of epilepsy have altered GABAAR number or
function1,2,15. GABAAR subunit expression is altered in the
hippocampi of experimental animals with recurrent seizures16
and in patients with temporal lobe epilepsy17,18. Angelman’s
syndrome is a human neurodevelopmental disorder associated
with severe mental retardation and epilepsy, which is linked to a
deletion mutation on chromosome 15q11-1320 in a region
encoding the GABAAR b3 subunit
21. Two mutations in the g2
subunit that impair GABAAR function
22, K289 M23 and R43Q24,
have been linked to a human syndrome of childhood absence
epilepsy and febrile seizures, and a loss-of-function mutation in
the a1 subunit causes autosomal dominant Juvenile Myoclonic
Epilepsy25. The R43Q mutation in the g2 subunit reduces BZ
sensitivity26 by altering GABAAR assembly
27–29 and trapping the
receptor in the endoplasmic reticulum30. Other point mutations in
GABAAR subunits have also been associated with generalized
epilepsies (see Fig. 2). Hence, GABAAR modulation by GABAergic
ASDs is likely critical to their antiseizure activity.vier Ltd. All rights reserved.
Fig. 1. Model of a GABAA receptor in the plasma membrane. A. A space-ﬁlling model of the pentomer in side view (A) and top view (B) based on the high sequence homology
with the nicotinic acetylcholine receptor. There are two binding sites for GABA, between a and b subunits (bent arrows), and one for BZs between the alpha and gamma
subunits (arrow). C. A schematic view shows the topology of each subunit with a large extracellular loop containing a cysteine loop and 4 transmembrane domains (M1-M4),
the second of which forms the chloride ion channel. Binding of GABA allows the channel to open and conduct Cl ions, resulting in the fast inhibitory post-synaptic potential
(IPSP). D. Putative arrangement of 5 subunits to form a pentamer with central chloride channel lined by the M2 subunit. [Derived from the published structure: RCSB PDB
Database PDB ID: 2BG9 from Unwin, N. (2005)198. Images modiﬁed from en.wikipedia.org/wiki/GABA_A_receptor, used with permission (public domain)].
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BZs were initially developed as anxiolytic agents in the 1950’s.
Chlordiazepoxide was introduced in 1960, followed by diazepam31Table 1
Antiseizure Drugs and their GABAAR Effects.
Anti-seizure drug Subunit speciﬁcity Site of action 
Benzodiazepines a1–3, a5; g a/g interface,
a1(H101)
Zolpidem a1 > a2,3; g a/g interface 
Barbiturates b subunits? M3 residues? 
Loreclezole b2, b3 B2(N289) 
Ganaxolone a, b, d, # with e a1(Q241) 
Topiramate a6 > a4 > a1-a2? unknown 
Felbamate unknown unknown 
Retigabine unknown unknown 
Losigamone unknown unknown 
Stiripentol a3, # with b1, e unknown 
Vigabatrin GABA transaminase 
Gabapentin,
pregabalin
Glutamic acid decarboxylase 
Valproic Acid Glutamic acid decarboxylase 
Tiagabine GAT-1 (GABA transporter) and nitrazepam.32 In 1965, diazepam was ﬁrst used to treat status
epilepticus in humans.33 Clonazepam was introduced in the 1970’s
primarily as an ASD,34 and clobazam, a 1,5 benzodiazepine, was
later developed as an ASD with less sedative effect.35 However, theGABAAR action Other mechanisms
Left shift of GABA
C/R curve, "
open frequency
Possible increased
GABAAR channel conductance
‘‘ ’’
" channel open time &
burst duration
Use-dependent Na+ channel block
Barbiturate-like? inhibits GABAAR at " concentration
Barbiturate-like, also "
open frequency
Open channel block at high conc.
Enhanced GABA currents Na+/Ca2+ channel block, AMPA/kainate
receptor block
Barbiturate-like Blocks NMDA receptor currents
Increased GABA IPSCs Opens KCNQ2/3 potassium channels
Enhanced GABA
receptor current
Use-dependent Na+ channel block
Barbiturate-like CYP450 inhibition
increases [GABA] –
" GABA synthesis? a2-d subunit of voltage-gated Ca2+ channel
" GABA synthesis? block of Na+, T-type Ca2+ channels
Blocks GABA reuptake
Fig. 2. Model of a prototype GABAAR subunit (based on a1 subunit diagram from Olsen & Tobin, 1990)
199 showing approximate locations of point mutations associated with
generalized epilepsies (see also Macdonald et al., 2012200) in black, and locations of point mutations associated with ASD sites of action. See text for details.
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produce less tolerance than the 1,4 BZs, but tolerance to 1,5 BZs
does occur.36
BZ activity at GABAARs is a function of the drug’s afﬁnity for the
BZ binding site and its intrinsic allosteric effect on the GABAAR. The
efﬁcacy of individual compounds varies widely. Most BZs in
clinical use are full agonists that maximally enhance GABAAR
activity. Flumazenil, a competitive antagonist used to reverse BZ-
induced sedation,37 binds to the BZ site without affecting GABAAR
function. Abecarnil,39 imidazenil,40 and bretazenil41 are ‘‘partial
agonists’’ at the BZ site which have antiseizure efﬁcacy in animal
models and appear less prone to tolerance.42 Several b-carbolines
are ‘‘inverse BZ agonists’’ that inhibit GABA binding43 and can
induce seizures or anxiety.44
Antiseizure Activity. BZs are effective against most experimental
seizure types, but individual drugs vary in their potency/efﬁcacy in
speciﬁc seizure models and their other clinical effects.45 BZs are
particularly effective against convulsive seizures induced by
pentylenetetrazol46 and less effective against tonic seizures
induced by maximal electroshock.47 BZs also slow the develop-
ment of kindling.48
GABAAR Subunits and BZ Pharmacology. BZ augmentation of
GABAAR currents requires a g subunit, and the selectivity of BZ
responsiveness is determined by which a subunits are present.5,49
The BZ binding site is located in a cleft between the extracellular
amino termini of the a and g subunits.51 The a1 subunit results in areceptor with high afﬁnity for the hypnotic, zolpidem, deﬁning the
‘‘BZ-1’’ (or V-1) receptor type.50 The a2 and a3 subunits result in
receptors with moderate zolpidem afﬁnity, termed BZ-2 receptors.
GABAARs containing the a5 subunit and/or the g3 subunit are
sensitive to diazepam but not to zolpidem and are termed BZ-3
receptors. GABAARs with the a4 or a6 subunits are insensitive to
most BZs.
The subunit composition not only determines the afﬁnity for
particular BZs, but also the clinical/behavioral effect of the BZ at
that receptor. The role of the a subunits in BZ pharmacology was
revealed by the discovery of a single histidine (H) residue found in
all BZ-sensitive a subunits (H101 in the rat a1 subunit), but not in
the BZ-insensitive a4 or a6 subunits, which instead have a
charged arginine (R) residue. This H residue was discovered in a
strain of ‘‘alcohol-non-tolerant’’ rats, which were found to have a
spontaneous point mutation in the a6 subunit (R100Q) that made
their a6-containing GABAARs (found mostly in the cerebellum)
diazepam-sensitive, accounting for their ethanol and BZ intoler-
ance.53 Mutation of R100 to H in a6 dramatically increased BZ
binding in this normally insensitive subunit, while mutation of
H101 to R in a1 reduced BZ sensitivity.52 BZ-insensitive a subunit
mutations were subsequently ‘‘knocked-in’’ to identify BZ
actions at receptors containing that subunit. In homozygous
a1(H101R) knock-in mice, the anxiolytic effect was intact, but
BZs were not protective against pentylenetetrazol-induced
convulsions and did not produce sedation or amnesia, suggesting
L.J. Greenﬁeld Jr. / Seizure 22 (2013) 589–600592that binding to the (wild type) a1 subunit is responsible for
sedative, amnestic and antiseizure actions.54 Moreover, the
sedative-hypnotic, zolpidem, showed no sedative effect in
a1(H101R) mice.55 Unfortunately, these ﬁndings underscore
the association between sedative and antiseizure efﬁcacy at a1-
containing GABAARs. Similarly, the anxiolytic
56 and myorelax-
ant57 properties of BZs appear to derive from a2- and a3-
containing GABAARs, while the a5 subunit was critical for
amnestic effects.58 BZs may also have a true analgesic effect
independent of their sedative and anxiolytic actions, associated
with the a2 and a3 more than a5 subunits.59 Since there is no
evidence of biophysically distinct effects of BZs on receptors
composed of different a subunits, the different  behavioral effects
are likely due to the brain regions and neuronal populations
expressing these speciﬁc GABAAR isoforms. New a2/a3 subunit-
selective BZs appear to be anxiolytic but not sedating,60 and non-
sedating antiseizure BZs that do not induce tolerance61 may also
be possible.
BZ Actions at GABAARs. BZs increase the amplitude
62 or decay
time63 of GABA-mediated inhibitory post-synaptic potentials
(IPSPs). Current noise ﬂuctuation analysis64 and single channel
studies65 demonstrated that the BZs increased the opening
frequency of the GABAAR chloride channel. In patch-clamp
recordings of CNS neurons, BZs produce a leftward shift of the
concentration-response curve for GABA,66 due to an increase in the
afﬁnity for GABA at its binding site, with no change in the kinetics
of channel gating65 or single channel conductance. In contrast, an
inverse agonist at the BZ site reduced the channel opening
frequency for a given GABA concentration. These ﬁndings are
consistent with binding studies showing the allosteric interaction
between the BZ and GABA binding sites. By increasing the afﬁnity
of the receptor for GABA through slowing the unbinding rate, the
BZs increase the current produced by low GABA concentrations,
but not by high GABA concentrations at which receptor binding is
saturated, as observed in the synaptic cleft67. Thus, BZs generally
do not increase the amplitude of miniature inhibitory postsynaptic
currents (mIPSCs) from individual synapses, but instead prolong
the mIPSC decay phase68 by slowing the dissociation of GABA from
the receptor.69 Prolongation of the mIPSC increases temporal and
spatial summation of multiple synaptic inputs, which in turn
increases the amplitude of stimulus-evoked polysynaptic IPSCs.
The BZs thus increase the inhibitory ‘‘tone’’ of GABAergic synapses,
which reduces the hypersynchronous ﬁring of neuron populations
that underlies seizures.1
An alternative mechanism for BZ enhancement of GABAAR
currents has been proposed based on the controversial ﬁnding
that BZs progressively increase GABAAR ‘‘single channel’’ conduc-
tance.70 Unlike prior reports of a 27 pS main conductance level
and a 19 pS subconductance level,65 Eghbali et al.70 found
conductance levels ranging from 8 to 53 pS in response to GABA
alone, and 70–80 pS in the presence of diazepam, with up to 7-fold
increase in conductance observed when diazepam was added. The
increases in conductance were seen predominantly in cell-
attached patches onto neurons expressing native receptors, but
were also observed in outside-out patches. They found similar
increases in channel conductance induced by pentobarbital,71
neuroactive steroids,72 propofol,73 and GABA itself.74 The same
group75 subsequently found that high conductance (>40 pS)
GABAAR channels were not observed in recombinant a1-b1-g2
GABAARs expressed in L929 cells, nor was conductance increased
by diazepam unless the GABAAR-associated protein (GABARAP)
was also co-expressed, apparently facilitating clustering of
GABAAR proteins through its interaction with the cytoplasmic
loop of the g2 subunit as occurs at synapses with native receptors.
Since peptides mimicking the intracellular g2 loop (g2 381–403)
self-associate, and application of this peptide to the cytoplasmicsurface of inside-out patches prevented the diazepam-induced
increase in conductance, they hypothesized that the apparent
single channel conductance changes induced by BZs are due to
synchronized openings of multichannel clustered GABAARs via
concerted action through the interacting cytoplasmic loops of
conjoined receptors. Such interactions might occur through
shared transmembrane domains between interacting receptors,
as observed in G-protein-coupled receptors.76 This hypothesis
could be addressed using concatenated subunits, chimeras and
other strategies. However, synchronization of multiple identical
channels by such a mechanism should still require a discrete 9 pS
unitary conductance of which the larger conductance states are
integer multiples, which has not been reported.
3. Barbiturates
Phenobarbital was synthesized by Emil Fischer at Bayer in 1911
and introduced as an ASD by Alfred Hauptmann in 1912. Its
tendency to produce sedation and cognitive slowing or confusion,
as well as paradoxical hyperactivity in children, has curtailed its
use in favor of more modern alternatives.77 In addition to their
enhancement of GABAAR currents, barbiturates also inhibit
repetitive action potential ﬁring at neuronal sodium channels78
by reducing fractional open time and shifting the potential of half-
maximal opening towards hyperpolarized potentials.79 These
actions contribute to both their antiseizure action and their
adverse effect proﬁle.
When co-applied with low concentrations of GABA, barbitu-
rates increased the mean open time, but had no effect on the
lengths of 3 distinct open state durations.80 The increase in mean
open time resulted from fewer openings in the shorter two
durations (O1 and O2) and more long duration (O3) openings.
There was also an increase in long burst durations, but no change
in the single channel opening frequency or in the closed
frequency duration histogram. The increase in channel open
time results in greater chloride current ﬂux and increased
likelihood that channel openings will summate, producing larger
inhibitory currents. In the absence of GABA, high concentrations
of pentobarbital (EC50 0.33 mM) and phenobarbital (EC50 3 mM)
directly activated GABAAR chloride currents with lower efﬁcacy
(smaller maximal currents) than GABA82. Barbiturate-activated
GABAAR currents were blocked by bicuculline and picrotoxin,
and at high concentrations both phenobarbital and pentobarbi-
tal produced open channel block that rapidly terminated the
induced currents. The concentrations involved in both direct
activation and open channel block are far higher than usual
therapeutic levels, thus the main antiseizure mechanism is likely
the GABAAR allosteric effect in concert with synaptic and
extrasynaptic GABA.
Unlike the BZs, barbiturate sensitivity does not require a
speciﬁc subunit composition. Homomeric b1 receptors expressed
in Xenopus oocytes were directly activated by pentobarbital even
though they were not responsive to GABA; these currents were
blocked by picrotoxin or penicillin but not bicuculline.83
Pentobarbital also induced current in both a1-b3 and b3
homomeric GABAARs.
84 At saturating GABA concentrations,
pentobarbital markedly potentiated a1-b3-d currents, increasing
desensitization and single channel open duration,85 suggesting
that barbiturates may be particularly effective at enhancing tonic
GABAAR currents at extrasynaptic sites activated by low GABA
concentrations. The e subunit, which increases spontaneous
GABAAR channel openings, signiﬁcantly reduced
86 but did not
completely eliminate87 barbiturate responsiveness when co-
expressed with a and b subunits. These ﬁndings suggest that
barbiturate sensitivity does not require either an a or a g subunit
as it is present in b homomeric receptors; however, presence of
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barbiturate responsiveness by altering the efﬁcacy of GABA for
activating the channel.
Chimera and mutagenesis studies have identiﬁed domains and
residues that contribute to barbiturate action, though in less detail
than for the BZs. Mutation of the proline (P228A) in the ﬁrst
transmembrane domain of the b1 subunit reduced barbiturate
enhancement of GABA-evoked currents in a1-b1-g2L GABAARs
while increasing apparent GABA afﬁnity, without otherwise
altering single channel kinetics.88 A chimera study using
constructs created from the amino terminal end of the b3 subunit
and the carboxyl terminal end of the r1 subunit, which forms
homomeric GABAC receptors that are insensitive to barbiturates,
found that residues of the b3 subunit involved in pentobarbital
binding to GABAARs are located downstream from the middle of
the M2 region.89 Similarly, mutation of a r1 tryptophan (W328) in
the third transmembrane domain to a hydrophobic residue
produced both allosteric and direct channel activation by
pentobarbital.90
4. Loreclezole
Loreclezole has antiseizure activity in a variety of seizure
models, acting more like a barbiturate than a BZ in that the
increase in seizure threshold produced by loreclezole was
potentiated rather than blocked by the BZ antagonist, ﬂumaze-
nil.91 In the hippocampal slice, loreclezole, potentiated paired
pulse inhibition92 and inhibited epileptiform discharges induced
by low Ca2+ or low Mg2+. Loreclezole strongly potentiated
recombinant GABAARs containing a b2 or b3 subunit but did
not enhance currents from b1-containing receptors.93 A single
asparagine residue (b2(N289) or b3(N290)) at the cytoplasmic
end of the 2nd transmembrane domain confers sensitivity to
loreclezole; this amino acid is a serine in the b1 subunit.94
Mutation of b1S290 to N conferred loreclezole sensitivity to b1-
containing GABAARs, while mutation of b2N289 or b3N290 to S
eliminated loreclezole enhancement. When both b1 and b3 were
co-expressed in the same receptor, loreclezole sensitivity was
abolished, suggesting a dominant effect of the b1 subunit.95
Coexpression with different alpha subunits altered the degree of
loreclezole potentiation (a1 = a2 = a3 > a5 > a4);96 expression
of a5 and b3 with the p subunit reduced loreclezole potentia-
tion,97 while a1-b3-e receptors showed normal loreclezole
enhancement.87
At higher concentrations (> 6 mM) loreclezole caused
concentration-dependent inhibition of GABAAR currents by
enhancing the rate of apparent desensitization.98 The effect
was inconsistent with open channel block as it was voltage
independent, non-competitive, and increased with increasing
GABA concentration. The BZ site was not involved as the
inhibition was not antagonized by ﬂumazenil and did not require
a g subunit. This ﬁnding has important clinical implications, since
inadvertent high levels of drug could inhibit rather than enhance
GABAAR function and potentially trigger seizure activity.
Loreclezole inhibited a1-b1-g2L GABAAR currents that were
not potentiated by low concentrations of loreclezole, suggesting
separate sites for enhancement and inhibition. At the single
channel level, high loreclezole concentrations decreased a1-b1-
g2L mean open time by decreasing the average durations of the
open states, and also increased the occurrence of a 20 ms closed
state. Loreclezole inhibition was equally effective when applied
to the intracellular side of the receptor, suggesting that its
inhibitory binding site was accessible from both sides of the
membrane, and pre-application of loreclezole prior to GABA
inhibited the subsequent GABAAR current, indicating that
binding did not require an open channel. Loreclezole was alsofound to inhibit r1 homomeric GABAC receptors with an IC50 of
0.5 mM, which was proposed as a rapid means of pharmacological
identiﬁcation of these receptors.99
5. Ganaxolone
Ganaxolone (3a-OH-3b-methyl-5a-pregnan-20-one) is the
3b-methylated synthetic analog of the neurosteroid, allopregna-
nolone, a natural metabolite of progesterone that allosterically
enhances GABAAR current. It has a broad range of antiseizure
activity in animal epilepsy models100 including seizures induced
by bicuculline, t-butylbicyclophosphorothionate (TBPS, a high
afﬁnity ligand for the GABAAR picrotoxin site), aminophylline and
corneal kindling, and is well tolerated and effective against
seizures in humans. Ganaxolone is currently under evaluation for
partial onset seizures. It may have special utility in women with
catamenial epilepsy who have increased seizures during periods of
low progesterone in the menstrual cycle, as well as in children with
infantile spasms.101
The antiseizure effect of neurosteroids is not due to action at the
progesterone receptor (PR), as exogenous allopregnanolone pre-
vented seizures in PR knockout mice.102 Moreover, progesterone’s
antiseizure effect requires metabolism to allopregnanolone, as it
was blocked by ﬁnasteride, a 5a-reductase inhibitor that blocks
allopregnanolone synthesis from progesterone. Hence, the antisei-
zure effect of allopregnanolone (and ganaxolone) is mediated by
GABAARs.
Speciﬁc neurosteroids can allosterically modulate GABAAR
activity, either positively or negatively, via distinct binding sites
on GABAARs.
104 Since a variety of GABAAR-interacting steroid
hormones are synthesized in the brain,105 these agents represent
endogenous modulators of GABAAR function. Allopregnanolone is
synthesized in two steps from progesterone: 5a-reductase
converts progesterone to 5a-dihydroprogesterone, then 3-a–
hydroxysteroid oxidoreductase reversibly converts 5a-dihydro-
progesterone to 3a-OH-5a-pregnan-20-one (allopregnanolone).
Addition of the 3b-methyl group on ganaxolone does not alter
binding to GABAARs, but prevents further metabolism of the 3a-
OH group and thus prolongs its GABAAR-modulating actions.
100
Ganaxolone enhanced GABA and BZ binding via positive allosteric
modulation of GABAAR activity, and at nanomolar concentrations
potentiated GABA-evoked currents at a1-b1-g2L, a2-b1-g2L or
a3-b1-g2L GABAARs expressed in Xenopus oocytes, while direct
activation of chloride ﬂux occurred to a limited extent only at
micromolar concentrations.100
The effects of GABAAR-enhancing neurosteroids on single
channel GABAAR currents were studied using androsterone
(5a-androstan-3a-ol-17-one) and pregnanolone (5b-pregnan-
3a-ol-20-one) but likely apply to other positive steroid
GABAAR modulators including ganaxolone. Like the barbitu-
rates and loreclezole, these agents increased the proportion of
openings to the two longer open states (O2 and O3) without
altering the intrinsic durations of those states, and produced
longer burst durations.106 There was no change in single
channel conductance. Unlike the barbiturates, however, the
neurosteroids also increased single channel opening frequency
and reduced closed time durations in all but the shortest closed
time distributions (thought to represent intraburst closures).
At high concentrations (10 mM), both agents reduced open
channel durations consistent with open channel (‘‘ﬂickering’’)
block.
The subunit selectivity of GABAAR-enhancing neurosteroids
was initially controversial. An early study107 of recombinant
receptors expressed from combinations of a1, a6, b3, g2 and d
showed loss of neurosteroid responsiveness with combinations
containing the delta subunit. There was also reduced sensitivity of
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development, when d subunit expression increases. These ﬁndings
were interpreted as showing inhibition of neurosteroid respon-
siveness by inclusion of the d subunit. However, mice in which the
d subunit was knocked out showed decreased behavioral
sensitivity to neurosteroids.108 Moreover, in receptors composed
of a1 or a6, b3 and either g2L or d, the greatest potentiation by
tetrahydrodeoxycorticosterone (THDOC) was seen in a1-b3-d
GABAARs.
109 At high concentrations (1 mM), THDOC inhibited this
isoform. There is currently consensus that d subunit-containing
receptors are more sensitive to neurosteroid enhancement, though
other subunits are also involved in mediating neurosteroid actions.
Presence of the a6 subunit reduced neurosteroid sensitivity.110
THDOC (1 mM) enhanced a1-b3-d more than a6-b3-d currents,
but increased the extent of desensitization and prolonged
deactivation for both receptor isoforms; a1-a6 and a6-a1
chimeras (spliced in transmembrane domain M1) suggested that
differences in deactivation rate and its voltage-dependence
correlated with N-terminal domains, while the extent of desensi-
tization and its voltage-dependence correlated with C-terminal
domains.111 In dentate granule cells from epileptic animals, an
increase in a4 subunit expression was associated with decreased
neurosteroid enhancement.112 In receptors composed of one a
subunit (from a2 through a5), b2 and g2S, neurosteroid
potentiation was dependent on the conserved glutamine residue
(a1(Q241)) in the ﬁrst transmembrane domain of the respective a
subunit.113 The d subunit did not affect neurosteroid binding but
likely inﬂuenced the efﬁcacy of neurosteroid potentiation. Muta-
tion of a1Q241 to L abolished neurosteroid potentiation, while
mutation to W mimicked the effect of steroids and prevented
further augmentation; the neighboring S240 residue also partici-
pated in steroid binding.114 A subsequent study using concatenat-
ed subunits demonstrated that a single functional binding site (not
disrupted by the Q241 mutation) was sufﬁcient for neurosteroid
modulation.115
6. GABAAR effects of other ASDs
6.1. Topiramate
Topiramate is a heterotricyclic sulfamate with several mecha-
nisms of action including inhibition of sodium and calcium
channels, inhibition of carbonic anhydrase, and augmentation of
GABA-evoked currents. Topiramate’s effects on GABAARs may
contribute both to its antiseizure efﬁcacy and its side effect proﬁle
including memory problems, fatigue and psychomotor slowing. It
is approved for partial and generalized seizures, the Lennox
Gastaut syndrome, and migraine.
Topiramate inhibited voltage-gated sodium channels, with a
left shift of the steady state inactivation curve116 resulting in
intermittent blockade of sustained repetitive action potential
ﬁring during prolonged depolarization.117 It also blocked repetitive
ﬁring in hippocampal CA3 neurons from spontaneously epileptic
rats, and reduced excitatory post-synaptic potentials and
responses to bath-applied glutamate, suggesting blockade of
post-synaptic glutamate receptors,118 affecting kainate-evoked
but not NMDA-evoked currents.119 Topiramate also inhibited both
L-type and non L-type high voltage activated calcium currents120
and reduced bicarbonate production via inhibition of carbonic
anhydrase,121 which may contribute to its antiseizure effect.
Topiramate (10 mM) enhanced chloride ﬂux into cerebellar
granule neurons stimulated by 10 mM GABA, but did not
signiﬁcantly increase chloride inﬂux alone.122 It also enhanced
GABA-evoked currents in cultured cortical neurons that were
insensitive to the BZ, clonazepam, and clonazepam-potentiated
GABA currents in topiramate-insensitive neurons, conﬁrming thattopiramate’s site of action on GABAARs is independent of the BZ
site.123 Subunit selectivity studies have been inconsistent.
Topiramate (1–100 mM) reversibly inhibited Cl currents evoked
by 1–10 mM GABA in Xenopus oocytes expressing a1-b2-g2S and
a2-b2-g2S GABAARs, and reduced the apparent desensitization
(‘‘current-fading rate’’) in a1-b2-g2S-expressing oocytes, but
potentiated GABA-evoked Cl currents and increased the desensi-
tization rate in a6-b2-g2S GABAARs, with no effect on a4-b2-g2S
receptors or mixed population GABAARs expressed from rat brain
mRNA.124 In contrast, another study found that topiramate could
both potentiate and directly activate b2 or b3-containing
heteromeric GABAARs, with greatest effect on a4-b3-g2S;
125
positive or negative effects on b1-containing GABAARs depended
on the co-expressed alpha subunit. Additional studies are needed
to clarify the site and mechanism of action.
6.2. Felbamate
Felbamate was launched as a promising novel ASD in 1993 with
an uncertain mechanism of action, but its use was curtailed after
early reports of aplastic anemia126 and hepatic failure.127
Felbamate inhibited binding of the GABA antagonist [3H]T-BOB
with a regional pattern different from that produced by GABA
agonists, bicuculline, zinc or neurosteroids,128 and enhanced
GABA-elicited Cl currents in cultured cortical neurons. Felbamate
enhancement was not blocked by ﬂumazenil, and felbamate did
not affect pentobarbital potentiation or PTX inhibition of GABA-
evoked currents, suggesting an independent site of action. It
prolonged the mean burst duration of GABA-activated single
channel currents, suggesting a barbiturate-like effect.129 Felba-
mate also blocked N-methyl-D-aspartate (NMDA) receptor cur-
rents, an alternative possible antiseizure mechanism.130 Derivative
compounds including ﬂuorofelbamate and carisbamate that are
not associated with hematopoietic or hepatic toxicity may revive
interest in felbamate–like agents.131
6.3. Ezogabine
Ezogabine (also known as retigabine) is a novel ASD effective in
a variety of animal models. Its primary effect is enhanced
activation of heteromeric potassium channels composed of the
KCNQ2 and KCNQ3 subunits132 which underlie the ‘‘M current’’
that is a major determinant of resting membrane potential and
neuronal excitability. However, ezogabine also dose-dependently
and reversibly potentiated GABAAR-dependent IPSC peak ampli-
tude, decay times and total charge transfer.133 EPSCs were
unaffected, and paired pulse depression was unchanged, suggest-
ing a post-synaptic effect at GABAARs. Ezogabine potentiated
GABA-induced currents in rat cortical neurons in a concentration-
dependent fashion at 10 mM and above.132 This action was not
antagonized by ﬂumazenil, indicating a non-BZ site of action.
Subunit dependence and binding site are not known.
6.4. Losigamone
Losigamone is a novel ASD which inhibited the persistent
component of sodium currents in hippocampal neurons at
depolarized potentials, suppressed sustained repetitive ﬁring134
and decreased the frequency of spontaneous action potentials
without affecting miniature post-synaptic current amplitudes.135
Losigamone stimulated 36Cl inﬂux into spinal cord neurons in the
absence of GABA, and potentiated 36Cl inﬂux stimulated by
submaximal GABA concentrations; both effects were blocked by
bicuculline or picrotoxin.136 Losigamone did not affect the speciﬁc
binding of [3H]GABA, [3H]ﬂunitrazepam, or [35S]t-butyl-bicyclo-
phosphorothionate (TBPS) to their receptors, and there was
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mixture. The site of action at GABAARs is unknown.
6.5. Stiripentol
Stiripentol is as an adjunct ASD which was thought to act by
inhibiting cytochrome P450 enzymes involved in metabolism of
conventional ASDs. Recently, stiripentol was found to enhance
recombinant GABAAR currents, with greater potentiation of a3-
containing receptors and reduced potentiation with the b1 or e
subunits.137 It caused a leftward shift in the GABA concentration-
response relationship without increasing maximal GABA-evoked
currents, and did not involve sites associated with neurosteroid or
loreclezole potentiation.137 Saturating barbiturate sites with
pentobarbital occluded stiripentol enhancement, and stiripentol
increased the duration but not the frequency of opening of GABAAR
channels, suggesting a barbiturate-like mechanism.138
6.6. GABA-enhancing agents
An additional mechanism for enhancing GABAAR-mediated
inhibition involves increasing the concentration or duration of
GABA in the synaptic cleft and perisynaptic/extrasynaptic sites.
Enhancing GABA synthesis or blocking its reuptake or catabolism
could prolong GABA IPSPs and increase perisynaptic spill-over,
increasing tonic/extrasynaptic GABA currents which likely play a
major role in seizure prevention.
6.7. Gabapentin and pregabalin
Gabapentin was designed as a GABA analog, and some studies
have suggested that it modulates the action of the GABA synthetic
enzyme, glutamic acid decarboxylase (GAD) and the glutamate
synthesizing enzyme, branched-chain amino acid transaminase,
resulting in increased GABA synthesis.139 Gabapentin increases
non-synaptic GABA responses from neuronal tissues in vitro and
increases GABA levels in brain.140 Its other (likely primary) mode of
action involves binding to the a2-d binding site on L- or P/Q-type
presynaptic voltage-gated calcium channels, presumably inhibit-
ing excessive neurotransmitter release141 by interfering with
calcium channel functional expression or trafﬁcking142. Pregaba-
lin, which binds to the a2-d calcium channel subunit with higher
potency, may have similar mechanisms of action. Most studies
emphasize the calcium channel as the primary site,143 though a
contributory effect on GABA metabolism is possible.144
6.8. Valproic acid
Valproic acid may affect GABA production, among other ASD
mechanisms. Valproate caused non-signiﬁcant increases in cere-
bral GABA levels but elevated brain GAD activity signiﬁcantly.145
Valproic acid increased GABA synthesis and release in brain
regions including substantia nigra,146 which is thought to be
involved in the control of seizure generation and propagation.147 It
also reduced the release of gamma-hydroxybutyric acid and
attenuated neuronal excitation induced by NMDA-type glutamate
receptors.147 Additional ASD mechanisms include enhancing
sodium channel inactivation (like phenytoin) and reducing T-type
Ca2+ channel currents (like ethosuximide),148 perhaps explaining
its utility against both partial onset and absence seizures.
6.9. Tiagabine
Tiagabine is a derivative of nipecotic acid that binds to the
presynaptic GAT-1 GABA transporter and blocks GABA reuptake,
without acting as a ‘‘false neurotransmitter.’’ In controlhippocampal slices, tiagabine alone induced a signiﬁcant
chloride conductance, suggesting that GAT-1 activity controls
the basal level of extracellular GABA.149 Tiagabine prolonged
hippocampal IPSC duration in a lamina-speciﬁc fashion, with
greater effect in stratum radiatum (167%) than stratum oriens
(115%).150 Tiagabine reduced the frequency of epileptiform
discharges in hippocampal slices exposed to low Mg2+ or 4-
aminopyridine.151 The ability of tiagabine to prolong GABA
currents was preserved in hippocampal slices from pilocarpine-
treated epileptic rats, hence the GAT-1 transporter remains a
functional target for regulating GABA levels in this model of
temporal lobe epilepsy.152 Tiagabine was effective as an adjunct
agent against partial onset seizures, though its prolonged
titration period, requirement for multiple daily doses and CNS
side effect proﬁle (dizziness, tremor, somnolence, mood dis-
turbances and rare psychotic symptoms) have limited its use.153
6.10. Vigabatrin
Vigabatrin (g-vinyl-GABA) has a unique mechanism of action,
functioning as a ‘‘suicide inhibitor’’ of GABA transaminase, the
primary enzyme for GABA catalysis. This leads to permanent
inhibition of the affected enzyme, requiring synthesis of new
GABA transaminase and hence prolonging the biological half-life
beyond its pharmacokinetic half-life of 8 hours.154 It is effective
against complex partial seizures,155 Lennox–Gastaut syndrome
and West Syndrome, for which it has become an alternative to
ACTH156 particularly in children with tuberous sclerosis.157
Vigabatrin increases the extracellular concentrations of GABA
both in vitro158 and in vivo.159 The anti-seizure effects of
increasing GABA concentration may be complex. Biphasic
responses to vigabatrin administration have been observed, with
an early proconvulsant effect.160 A biphasic effect was also seen on
after-discharge duration with an early facilitation of the limbic
pattern of epileptiform discharge and later suppression at higher
doses.161 Elevated GABA concentrations may increase neuronal
synchronization, particularly of thalamic neurons in absence
epilepsy, and there have been several reports of vigabatrin
worsening absence seizures or precipitating absence status
epilepticus.162
A major limitation to the use of vigabatrin is the relatively high
incidence of vision disturbance associated with chronic use. In 21
of 30 children treated with vigabatrin who were screened for vision
disturbances despite no report of visual symptoms, 4 had visual
ﬁeld constrictions, which did not improve after discontinuation of
the drug.163 One study associated visual disturbances with
infantile spasms rather than the drug.164 The prevalence of vision
problems ranged from 10 to 40% of pediatric and adult patients
exposed to vigabatrin.165 This adverse effect may be directly
related to elevated GABA concentrations, as hippocampal neurons
grown in depolarizing conditions (25 mM KCl) showed 20% loss of
MAP-2-positive neurons in the presence of vigabatrin, which was
mimicked by GABA (100 mM) and blocked by bicuculline or
picrotoxin.166 The cellular mechanism of this toxicity is not
entirely clear, but in situations in which GABA is depolarizing,
excessive GABA could promote calcium entry through L-type
(slowly desensitizing) voltage-gated calcium channels,167 which in
turn could result in activation of caspases and cell death.168
7. Excitatory GABAA currents
Early in CNS development, neurons express the Na+/K+/Cl
cotransporter, NKCC1, rather than the K+/Cl cotransporter, KCC2,
which is expressed in adult neurons. NKCC1 increases intracellular
Cl resulting in a depolarizing Cl reversal potential, while KCC2
exports Cl yielding the hyperpolarizing Cl reversal potential
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be excitatory during early development.170 Excitatory GABAAR
currents may play a trophic role in neuronal migration and
connectivity,171 but may also contribute to epileptogenesis.172
Endogenous GABA appears to be proconvulsant in early postnatal
rat hippocampal slices, as GABAA antagonists blocked epileptiform
activity induced by depolarization with high external [K+]173.
However, BZ and barbiturate antiseizure efﬁcacy appear to be
intact, likely because persistent opening of GABAAR channels (in
the presence of allosteric agents) may reduce the depolarizing
chloride reversal potential, resulting in ‘‘shunt’’ inhibition.
Alternatively, subthreshhold GABA-evoked depolarization may
inactivate sodium channels and prevent action potential ﬁring.174
The current through GABAAR channels can also be altered by
changes in intracellular bicarbonate, [HCO3
],169 which can ﬂow
through the channel.175 Changes in [HCO3
] may underlie reduced
synaptic GABA currents during development of BZ tolerance.176
Depolarizing GABAAR currents may also be a source of interictal
spike activity, as observed in epileptic subiculum neurons in
hippocampal brain slices from patients with temporal lobe
epilepsy.177 Changes in the GABA current reversal potential might
also explain why diazepam can be less effective in children with
epileptic encephalopathies,178 and rarely can cause status epilep-
ticus in patients with the Lennox Gastaut syndrome.179
Bumetanide, an inhibitor of NKCC-1 used clinically as a potent
loop diuretic, has been proposed as an adjunctive agent to reduce
intraneuronal chloride accumulation and reverse the depolarizing
chloride gradient that makes GABAARs excitatory, particularly in
the neonatal setting.170 Bumetanide improved the responsiveness
of hippocampal slices to phenobarbital in reducing epileptiform
discharges induced by low Mg2+,180 and also suppressed electro-
graphic seizures in neonatal rats.172 Depolarizing GABA currents
may occur in cortical more than subcortical brain regions, possibly
explaining the electroclinical uncoupling that occurs with pheno-
barbital in neonatal seizures.181
Bumetanide has been used successfully in a single reported
human neonate with seizures,182 and a clinical trial
(NCT00830531) is in progress. However, elimination of the
depolarizing Cl gradient during development may have adverse
consequences; a permanent reduction in AMPAR-mediated
excitatory neurotransmission and sensorimotor gating deﬁcits
were observed after bumetanide exposure in neonatal rats.183 Such
potential adverse effects will have to be weighed against the
beneﬁts associated with seizure termination or prevention.
8. GABAAR subunit changes and ASD efﬁcacy in epilepsy and
status epilepticus
There is considerable evidence that GABAAR composition and
function change with epilepsy, both acutely in the setting of status
epilepticus and in chronic epilepsy. During status epilepticus, there
is a rapid change in GABAAR function that reduces BZ sensitivity,
184
apparently due to activity-dependent internalization of GABAARs
and replacement with BZ-insensitive receptors.185 Kainic acid-
induced status epilepticus in young (postnatal day 9) rats altered
the normal developmental pattern of GABAAR subunit matura-
tion,186 preventing the normal switch from a2 to a1-containing
GABAARs. These changes correlate with the ﬁnding in animal
models15,184,187 and humans188,189 that BZs are effective early in
the course of status epilepticus but lose their potency and efﬁcacy
for termination of status with longer seizure duration. These
ﬁndings increase the urgency for treatment of status epilepticus
early in its course, and also suggest the need to ﬁnd alternative
treatments that retain efﬁcacy in refractory status epilepticus, or
methods to prevent or reverse the GABAAR changes that occur with
prolonged seizures.In the pilocarpine model of temporal lobe epilepsy, the a1
subunit in dentate granule neurons was downregulated and a4
subunit was upregulated,190 while in younger (postnatal day 20)
animals, the a1 subunit was increased after status epilepticus.191
GABAAR subunit changes after pilocarpine-induced status are
associated with altered physiological properties including reduced
neurosteroid sensitivity and an increase in a4-containing recep-
tors colocalized with synapses rather than extracellular sites.112
Such changes might contribute to the propensity for spontaneous
seizures or alternatively represent a functional adaptation to
reduce seizure expression. Substitution of a1 with a4 might
reduce synaptic (phasic) but increase extrasynaptic (tonic)
inhibition, and BZ sensitivity would be lost in a4-containing
receptors. Using an adenovirus vector to insert the a1 subunit gene
driven by the a4 promoter resulted in a decrease in seizure
frequency, suggesting that the GABAAR subunit changes were
contributory toward epileptogenesis.192 Hence, altering GABAAR
subunit expression in brain regions critical to seizure development
may provide a new therapeutic strategy for seizure prevention.
Alternatively, novel ASDs targeting the speciﬁc epilepsy-associated
subunit composition might provide a less invasive approach
toward seizure control.
Long term exposure to the GABAAR allosteric agents
themselves can alter GABAAR composition and function. In rat
pups exposed to therapeutic concentrations of diazepam or
phenobarbital from postnatal day 10 through 40, then tapered
for 2 weeks and euthanized on postnatal day 90 showed
increased mRNA expression in dentate granule neurons for
GAT-1, 3 and 4, GABAAR subunits a4, a6, b3, d and u and GABAB
receptor subunit R1, and decreased mRNA expression for GAD65,
GAD67 and GABAAR subunits a1 and a3.
193 Tolerance- and
dependence-associated changes in GABAAR subunit composition
with chronic use of BZs194,195 and barbiturates196,197 have been
reported, and may reﬂect tolerance to either the antiseizure or
adverse CNS effects. However, these ﬁndings suggest that not
only seizures, but their prolonged treatment with GABAergic
agents, can alter inhibitory neuronal function for extended
periods or even permanently, with possible cognitive and
behavioral consequences that must be considered when
contemplating chronic GABAergic ASD use.
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